{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=niraparib&page=3", "query": { "intervention": "niraparib", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 105, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=niraparib&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=niraparib&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T02:46:35.203Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03209401", "title": "Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Homologous Recombination Deficiency" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2017-10-13", "completion_date": "2023-10-16", "has_results": false, "last_update_posted_date": "2024-02-05", "last_synced_at": "2026-10-26T02:46:35.203Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Washington D.C., District of Columbia • Hackensack, New Jersey + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03209401" }, { "nct_id": "NCT06212583", "title": "High-Risk Metachronous Oligometastatic Prostate Cancer Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Oligometastatic Disease" ], "interventions": [ { "name": "niraparib/abiraterone acetate", "type": "DRUG" }, { "name": "Stereotactic ablative radiation therapy (SABR)", "type": "RADIATION" }, { "name": "Androgen deprivation therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 88, "start_date": "2024-04-17", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-26T02:46:35.203Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06212583" }, { "nct_id": "NCT03307785", "title": "Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Metastatic Cancer", "Advanced Cancer", "Solid Tumor", "Non Small Cell Lung Cancer Metastatic", "Non Small Cell Lung Cancer Stage IIIB", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "TSR-042", "type": "DRUG" }, { "name": "Carboplatin-Paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "TSR-022", "type": "DRUG" }, { "name": "Carboplatin-Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin-Nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2017-10-12", "completion_date": "2024-12-11", "has_results": true, "last_update_posted_date": "2025-11-25", "last_synced_at": "2026-10-26T02:46:35.203Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Encinitas, California • San Marcos, California + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "San Marcos", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03307785" }, { "nct_id": "NCT03154281", "title": "Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "niraparib", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avera McKennan Hospital & University Health Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2017-07-26", "completion_date": "2023-05-01", "has_results": true, "last_update_posted_date": "2024-08-01", "last_synced_at": "2026-10-26T02:46:35.203Z", "location_count": 1, "location_summary": "Sioux Falls, South Dakota", "locations": [ { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03154281" }, { "nct_id": "NCT02500901", "title": "Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Paul Mathew, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 2, "start_date": "2016-03", "completion_date": "2016-05-10", "has_results": true, "last_update_posted_date": "2019-10-21", "last_synced_at": "2026-10-26T02:46:35.203Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02500901" }, { "nct_id": "NCT01905592", "title": "A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms, Breast", "Carcinoma of Breast", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "Ovarian Neoplasms" ], "interventions": [ { "name": "niraparib", "type": "DRUG" }, { "name": "Physician's choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 216, "start_date": "2014-02-25", "completion_date": "2021-10-26", "has_results": true, "last_update_posted_date": "2022-11-15", "last_synced_at": "2026-10-26T02:46:35.203Z", "location_count": 25, "location_summary": "Tucson, Arizona • Los Angeles, California • Fort Myers, Florida + 20 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01905592" }, { "nct_id": "NCT04701645", "title": "Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer", "Ovarian Cancer Stage III", "Ovarian Cancer Stage IV", "Fallopian Tube Cancer Stage IV", "Fallopian Tube Cancer Stage III" ], "interventions": [ { "name": "Microdevice", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2022-11-01", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-10-26T02:46:35.203Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04701645" }, { "nct_id": "NCT03404960", "title": "Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Niraparib + Nivolumab", "type": "DRUG" }, { "name": "Niraparib + Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2018-01-31", "completion_date": "2024-10-09", "has_results": true, "last_update_posted_date": "2025-10-10", "last_synced_at": "2026-10-26T02:46:35.203Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03404960" }, { "nct_id": "NCT04221503", "title": "Niraparib/TTFields in GBM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Recurrent Glioblastoma", "GBM" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Optune", "type": "DEVICE" }, { "name": "Planned surgical resection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 30, "start_date": "2019-12-30", "completion_date": "2026-01", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-10-26T02:46:35.203Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04221503" }, { "nct_id": "NCT03981796", "title": "A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Dostarlimab", "type": "BIOLOGICAL" }, { "name": "Placebo matching dostarlimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Niraparib", "type": "DRUG" }, { "name": "Placebo matching Niraparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 785, "start_date": "2019-07-18", "completion_date": "2026-11-26", "has_results": false, "last_update_posted_date": "2025-09-03", "last_synced_at": "2026-10-26T02:46:35.203Z", "location_count": 59, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 49 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03981796" } ] }